Hyperfine Inc (HYPR)vsJohnson & Johnson (JNJ)
HYPR
Hyperfine Inc
$1.87
+12.65%
HEALTHCARE · Cap: $163.54M
JNJ
Johnson & Johnson
$227.19
-1.16%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 710377% more annual revenue ($96.36B vs $13.56M). JNJ leads profitability with a 21.8% profit margin vs -262.3%. JNJ earns a higher WallStSmart Score of 59/100 (C).
HYPR
Avoid25
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
-41.6%
Fair Value
$160.43
Current Price
$227.19
$66.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 128.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.06 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 25/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is an innovative leader in medical technology, renowned for developing the first FDA-cleared portable MRI system that revolutionizes access to imaging at the point of care. By delivering high-quality imaging directly at the bedside, Hyperfine enhances patient care and streamlines clinical decision-making, addressing the growing demand for efficient and accessible diagnostic solutions. The company's focus on cost efficiency and patient convenience uniquely positions it within the evolving healthcare landscape, making it a compelling opportunity for institutional investors seeking to invest in transformative healthcare advancements.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?